Denali Therapeutics Inc. Capital Expenditures
Denali Therapeutics Inc. (DNLI) reported Capital Expenditures of $3.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $805.00K, a 81.18% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $2.47M, a 51.44% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $1.52M, a 70.07% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was -$1.38M, a 135.48% decline year-over-year.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $9.50M, a 40.28% decline from fiscal 2024.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $15.91M, a 22.98% increase from fiscal 2023.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $12.94M, a 27.44% decline from fiscal 2022.
- Denali Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $17.83M, a 109.80% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $805.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.27M 10-Q · filed 2026-08-06 | $4.79M derived: sum of 3 quarters · filed 2026-08-06 | $3.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.47M 10-Q · filed 2026-05-07 | $3.99M derived: sum of 2 quarters · filed 2026-05-07 | $2.61M derived: sum of 3 quarters · filed 2026-05-07 | $6.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $146.00K derived: sum of 2 quarters · filed 2026-02-26 | $4.42M derived: sum of 3 quarters · filed 2026-08-06 | $9.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.90M derived: sum of 2 quarters · filed 2026-08-06 | $7.98M 10-Q · filed 2025-11-06 | $13.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.36M 10-Q · filed 2026-08-06 | $14.45M derived: sum of 3 quarters · filed 2026-08-06 | $18.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.08M 10-Q · filed 2026-05-07 | $10.17M derived: sum of 2 quarters · filed 2026-05-07 | $14.05M derived: sum of 3 quarters · filed 2026-05-07 | $18.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.98M derived: sum of 2 quarters · filed 2026-02-26 | $13.76M derived: sum of 3 quarters · filed 2026-02-26 | $15.91M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.67M derived: sum of 2 quarters · filed 2025-11-06 | $10.82M 10-Q · filed 2025-11-06 | $13.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $6.94M 10-Q · filed 2025-08-11 | $9.17M derived: sum of 3 quarters · filed 2026-02-26 | $11.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.15M 10-Q · filed 2025-05-06 | $4.38M derived: sum of 2 quarters · filed 2026-02-26 | $6.45M derived: sum of 3 quarters · filed 2026-02-26 | $12.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.30M derived: sum of 2 quarters · filed 2026-02-26 | $10.15M derived: sum of 3 quarters · filed 2026-02-26 | $12.94M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $7.92M derived: sum of 2 quarters · filed 2024-11-06 | $10.70M 10-Q · filed 2024-11-06 | $15.55M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $5.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $8.64M 10-Q · filed 2024-08-01 | $13.48M derived: sum of 3 quarters · filed 2025-02-27 | $19.54M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.79M 10-Q · filed 2024-05-07 | $7.63M derived: sum of 2 quarters · filed 2025-02-27 | $13.69M derived: sum of 3 quarters · filed 2025-02-27 | $16.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $10.90M derived: sum of 2 quarters · filed 2025-02-27 | $13.79M derived: sum of 3 quarters · filed 2025-02-27 | $17.83M 10-K · filed 2025-02-27 |
| 2022-09-30 | $6.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $8.94M derived: sum of 2 quarters · filed 2023-11-07 | $12.98M 10-Q · filed 2023-11-07 | $16.04M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.93M 10-Q · filed 2023-08-08 | $9.99M derived: sum of 3 quarters · filed 2024-02-28 | $11.86M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $4.04M 10-Q · filed 2023-05-08 | $7.09M derived: sum of 2 quarters · filed 2024-02-28 | $8.97M derived: sum of 3 quarters · filed 2024-02-28 | $9.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.93M derived: sum of 2 quarters · filed 2024-02-28 | $5.70M derived: sum of 3 quarters · filed 2024-02-28 | $8.50M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.65M derived: sum of 2 quarters · filed 2022-11-03 | $5.45M 10-Q · filed 2022-11-03 | $6.64M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $772.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.57M 10-Q · filed 2022-08-08 | $4.77M derived: sum of 3 quarters · filed 2023-02-27 | $5.47M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $2.80M 10-Q · filed 2022-05-05 | $4.00M derived: sum of 2 quarters · filed 2023-02-27 | $4.70M derived: sum of 3 quarters · filed 2023-02-27 | $5.02M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.90M derived: sum of 2 quarters · filed 2023-02-27 | $2.22M derived: sum of 3 quarters · filed 2023-02-27 | $3.10M 10-K · filed 2023-02-27 |
| 2020-09-30 | $706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.02M derived: sum of 2 quarters · filed 2021-11-04 | $1.90M 10-Q · filed 2021-11-04 | $4.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $315.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $1.19M 10-Q · filed 2021-08-04 | $3.97M derived: sum of 3 quarters · filed 2022-02-28 | $6.81M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $879.00K 10-Q · filed 2021-05-05 | $3.65M derived: sum of 2 quarters · filed 2022-02-28 | $6.50M derived: sum of 3 quarters · filed 2022-02-28 | $16.77M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.62M derived: sum of 2 quarters · filed 2022-02-28 | $15.89M derived: sum of 3 quarters · filed 2022-02-28 | $17.92M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $13.12M derived: sum of 2 quarters · filed 2020-11-05 | $15.15M 10-Q · filed 2020-11-05 | $16.58M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $10.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $12.30M 10-Q · filed 2020-08-07 | $13.74M derived: sum of 3 quarters · filed 2021-02-26 | $14.58M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $2.03M 10-Q · filed 2020-05-07 | $3.46M derived: sum of 2 quarters · filed 2021-02-26 | $4.31M derived: sum of 3 quarters · filed 2021-02-26 | $4.88M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.28M derived: sum of 2 quarters · filed 2021-02-26 | $2.86M derived: sum of 3 quarters · filed 2021-02-26 | $3.39M 10-K · filed 2021-02-26 |
| 2018-09-30 | $847.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $1.42M derived: sum of 2 quarters · filed 2019-11-06 | $1.96M 10-Q · filed 2019-11-06 | $3.03M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.11M 10-Q · filed 2019-08-06 | $2.18M derived: sum of 3 quarters · filed 2020-02-27 | $2.55M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $537.00K 10-Q · filed 2019-05-08 | $1.61M derived: sum of 2 quarters · filed 2020-02-27 | $1.98M derived: sum of 3 quarters · filed 2020-02-27 | $2.54M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.44M derived: sum of 2 quarters · filed 2020-02-27 | $2.01M derived: sum of 3 quarters · filed 2020-02-27 | $2.88M 10-K · filed 2020-02-27 |
| 2017-09-30 | $367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $936.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.80M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $569.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.44M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $868.00K 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $6.13M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |